1 Ferro F, et al. One year in review 2016: Sjogren’s syndrome. Clin Exp Rheumatol. 2016;34(2):161–71.
2 Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjogren syndrome. Nat Rev Rheumatol. 2016;12(8):456–71.
3 Vivino FB, et al. New Treatment Guidelines for Sjogren’s Disease. Rheum Dis Clin North Am. 2016;42(3):531–51.
4 Macfarlane GJ, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318–28.
5 Fox RI, Fox CM. Sjogren Syndrome: Why Do Clinical Trials Fail? Rheum Dis Clin North Am. 2016;42(3):519–30.
6 Brito-Zeron P, et al. Treating the Underlying Pathophysiology of Primary Sjogren Syndrome: Recent Advances and Future Prospects. Drugs. 2016;76(17):1601–23.
7 Nocturne G, et al. Use of Biologics in Sjogren’s Syndrome. Rheum Dis Clin North Am. 2016;42(3):407–17.
8 Souza FB, et al. Rituximab Effectiveness and Safety for Treating Primary Sjogren’s Syndrome (pSS): Systematic Review and Meta-Analysis. PLoS One. 2016;11(3):e0150749.
9 Bowman SJ, et al. Randomized Controlled Trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren’s Syndrome. Arthritis Rheumatol, 2017.
10 Karmacharya P, et al. Rituximab-induced serum sickness: A systematic review. Semin Arthritis Rheum. 2015;45(3):334–40.